---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-169612"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:43:14.650085+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vera's atacicept shows 43% placebo-adjusted proteinuria reduction at week 36 in Phase 2b IgAN trial

## Summary
- Atacicept 150 mg achieved 43% placebo-adjusted UPCR reduction (PP, p=0.003) and 35% (ITT, p=0.012).
- Patients on atacicept had stable eGFR vs. placebo decline; delta 11% (p=0.038), 5.8 mL/min/1.73 m² difference.
- Gd-IgA1 reduced 64% from baseline (p<0.0001); safety consistent with prior studies, low SAE rate (3% vs 9% placebo).
- Phase 3 ORIGIN 3 trial initiated June 2023; topline results expected H1 2025, BLA submission H2 2025.
- Company targets commercial launch in 2026 if atacicept receives FDA approval for IgAN.

## SEC filing metadata
- accession: 0001193125-23-169612
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312523169612/0001193125-23-169612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312523169612/d522707d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-169612
- JSON: https://secwatch.observer/filing/0001193125-23-169612.json
- Plain text: https://secwatch.observer/filing/0001193125-23-169612.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.